You are probably well aware of the enthusiasm around weight-loss drugs; Wegovy, Ozempic and Zepbound to name a few. Their performance has raised interest in those who are considering using them for their same effects as lifestyle drugs…
Did we see ripples of cautious optimism from the JP Morgan conference? The industry is certainly ready for the small uplift in last year’s FDA approvals, and for biotech dealmaking to continue.